Wilding JPH - Search Results

1

Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.

Evans M, Morgan AR, Yousef Z, Ellis G, Dashora U, Patel DC, Brown P, Hanif W, Townend JN, Kanumilli N, Moore J, Wilding JPH, Bain SC. Evans M, et al. Among authors: wilding jph. Drugs. 2021 Jul;81(11):1243-1255. doi: 10.1007/s40265-021-01538-6. Epub 2021 Jun 23. Drugs. 2021. PMID: 34160822

2

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Nair S, Wilding JP. Nair S, et al. J Clin Endocrinol Metab. 2010 Jan;95(1):34-42. doi: 10.1210/jc.2009-0473. Epub 2009 Nov 5. J Clin Endocrinol Metab. 2010. PMID: 19892839 Review.

3

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group. Wilding JP, et al. Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003. Ann Intern Med. 2012. PMID: 22431673 Free article. Clinical Trial.

4

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Wilding JP, et al. Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187. Epub 2013 Aug 29. Diabetes Obes Metab. 2014. PMID: 23911013 Clinical Trial.

5

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.

Boyle LD, Wilding JP. Boyle LD, et al. Expert Opin Emerg Drugs. 2013 Sep;18(3):375-91. doi: 10.1517/14728214.2013.831405. Expert Opin Emerg Drugs. 2013. PMID: 23968378 Review.

6

Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.

Wilding JP, Bain SC. Wilding JP, et al. Diabet Med. 2016 Jul;33(7):864-76. doi: 10.1111/dme.13021. Epub 2015 Dec 8. Diabet Med. 2016. PMID: 26525806 Review.

7

Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.

Wilding JP, Rajeev SP, DeFronzo RA. Wilding JP, et al. Diabetes Care. 2016 Aug;39 Suppl 2:S154-64. doi: 10.2337/dcS15-3005. Diabetes Care. 2016. PMID: 27440828 Review.

8

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice.

Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, Hicks D, James J, Newland-Jones P, Patel D, Viljoen A. Wilding J, et al. Diabetes Ther. 2018 Oct;9(5):1757-1773. doi: 10.1007/s13300-018-0471-8. Epub 2018 Jul 23. Diabetes Ther. 2018. PMID: 30039249 Free PMC article. Review.

9

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Among authors: wilding jph. Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10. Lancet. 2019. PMID: 30424892

10

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Kato ET, et al. Among authors: wilding jph. Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18. Circulation. 2019. PMID: 30882238 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

324 results

Search Page